Long intergenic non-protein coding RNA 589 (LINC00589)

Long intergenic non-protein coding RNA 589 (LINC00589), also known as TSLNC8 and C8orf75, is a cytoplasmic long noncoding RNA located on chromosome 8p12[1][2][3][4]. LINC00589 functions as a competing endogenous RNA (ceRNA), primarily sponging miR-100 and miR-452, thereby relieving miRNA-mediated repression of tumor suppressors like DLG5 and PRDM16[1]. It acts as a *tumor suppressor* in breast cancer, hepatocellular carcinoma, non-small cell lung cancer, and glioma, limiting cell proliferation, metastasis, and chemoresistance, and promoting apoptosis[1][2][4]. Notably, in HER2-positive breast cancer, LINC00589 is downregulated in trastuzumab-resistant tumors and its expression correlates with therapeutic response, serving both a diagnostic and prognostic biomarker role[1]. However, its function can be context-dependent, exhibiting oncogenic properties in pancreatic cancer[1]. At the molecular level, LINC00589 modulates drug resistance and stem cell-like traits through ceRNA networks, impacting key signaling pathways such as IL-6/STAT3/HIF-1a[2][4].

Other names

TSLNC8 (Tumor suppressor lncRNA on chromosome 8p12)C8orf75LINC00589

Not targeted directly by small molecules; modulates resistance/sensitivity by acting as a ceRNA (sponging miR-100, miR-452), which influences expression of tumor suppressor proteins (DLG5, PRDM16). Its modulation leads to altered therapeutic response to drugs like trastuzumab in HER2-positive breast cancer.